Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTS-2: Adjuvant Chemotherapy of Three-step Regimens in Ovarian Cancer
NCT04520074Phase 3Recruiting
- Sponsor
- Fudan University
- Start
- Oct 2021
- Primary completion
- Sep 2027
- Modality
- Nanoparticles, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 3 trial of cyclophosphamide, etoposide, carboplatin, Cisplatin micelle injection (HA132) in Epithelial Ovarian Cancer (EOC), fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Fudan University. Started Oct 2021; status: recruiting.
02
Drugs
cyclophosphamideetoposidecarboplatinCisplatin micelle injection (HA132)
03
Conditions
Epithelial Ovarian Cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT04520074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04520074.